Advanced or Metastatic Solid Tumors
70
18
29
19
Key Insights
Highlights
Success Rate
56% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
21.4%
15 terminated out of 70 trials
55.9%
-30.6% vs benchmark
0%
0 trials in Phase 3/4
53%
10 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (70)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors